NCT06702670 Anticholinergics for Cervical Edema in Labor
| NCT ID | NCT06702670 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Labor Dystocia |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-25 |
| Primary Completion | 2027-03-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 200 participants in total. It began in 2025-03-25 with a primary completion date of 2027-03-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to is to determine the clinical effectiveness of a single dose of intravenous (IV) medication for the prevention of labor arrest and cesarean delivery in primiparous women undergoing trial of labor.
Eligibility Criteria
Inclusion Criteria: * Primiparous * Viable single intrauterine pregnancy -≥ 34 weeks of gestation * Ruptured membranes * Category I tracing at time of inclusion * Active phase of labor (\>=6 cm of cervix dilation) Exclusion Criteria: * Category II or III tracing * Allergy to the study medication (IV Diphenhydramine)
Contact & Investigator
Samantha Antonioli, MD
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT06702670 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Labor Dystocia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06702670 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06702670 currently recruiting?
Yes, NCT06702670 is actively recruiting participants. Contact the research team at Samantha.Hentosh@uth.tmc.edu for enrollment information.
Where is the NCT06702670 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06702670 clinical trial?
NCT06702670 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Samantha Antonioli, MD at The University of Texas Health Science Center, Houston. The trial plans to enroll 200 participants.